MedTrace Logo

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

NCT04762459 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 606

Last updated 2022-02-24

No results posted yet for this study

Summary

This is a multicenter, randomized, open label, phase III study.

Conditions

  • Non-small Cell Lung Carcinoma

Interventions

DRUG

Almonertinib

Almonertinib 110mg PO once daily

DRUG

Pemetrexed

500 milligrams per square meter (mg/m²) Pemetrexed

DRUG

Cisplatin

75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • GeneCast Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2026-05-31
Completion
2029-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04762459 on ClinicalTrials.gov